New study aims to catch pancreatic cancer sooner in diabetics
NCT ID NCT04662879
First seen Jun 26, 2026 · Last updated Sep 09, 2026 · Updated 3 times
Summary
This large study is testing whether a risk-scoring tool (called ENDPAC) can identify people with new-onset diabetes who are at higher risk for pancreatic cancer. About 8,800 participants aged 50-85 will have their medical records checked for age, weight changes, and blood sugar trends. Those flagged as high risk will get a CT or MRI scan to look for early signs of pancreatic cancer. The goal is to see if this approach can detect the cancer earlier than usual.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- What this could lead to
- If successful, this could lead to a screening method that catches pancreatic cancer earlier in people with new-onset diabetes, potentially improving survival.
- What could go wrong
- This is an observational study, not a treatment trial. The algorithm may not prove accurate enough for widespread use, and early detection does not guarantee better outcomes.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
8,869 people
The number who actually took part.
- Started
-
Oct 2021
- Expected to finish
-
Jan 2028
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
50 to 85 years
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Patient must have given institutional consent for minimal risk studies. * Patient must be ≥50 and ≤85 years of age at the time of diagnosis \[index date Parameters of Diabetes Mellitus (PDM)\]. * Patient must have index weight and left-window weight values available in electronic medical record (EMR). * Patient must have hyperglycemia and/or diabetes as one of the following (all glycemic parameters, except for HbA1c, must be measured in an outpatient setting): A. Glycated hemoglobin (HbA1c) ≥ 6.5% OR B. Any (2) PDMs on consecutive (≤90 days between PDMs) or simultaneous testing: * Fasting Blood Glucose (FBG) ≥126 mg/dl * Glycated hemoglobin (HbA1c) ≥ 6.5% * Random Blood Glucose (RBG) ≥200 mg/dl * 2 hour Post Glucose (PG) ≥ 200mg (11.1 mmol/L) during oral glucose tolerance test (OGTT) OR C. Any one (1) PDM present followed by an anti- diabetes medication ≤90 days after the index PDM date * Patient must have ≥1 glycemic parameter measured in the past 91-548 days prior to the index PDM date (Left Window) without meeting inclusion criteria A, B, or C. * For Intervention Sites, patients must meet inclusion criteria A, B, or C ≤90 days prior to enrollment. Exclusion Criteria: * Patient has declined institutional consent for minimal risk studies. * Patient must not have any known past history of hyperglycemia and/or diabetes as defined by inclusion criteria A, B, or C \*Transient diabetes (e.g. gestational and steroid-induced) is not an exclusion. * Patient must not be on ongoing active treatment for cancer, and/or carry a current diagnosis of any cancer (except non-melanoma skin cancer). Non-invasive cancer of any organ (carcinoma-in-situ/high grade dysplasia) is not an exclusion. \*Ongoing work up for suspicion of pancreatic cancer is not an exclusion. * Patient must not have had a definitive diagnosis of pancreatic cancer prior to index PDM date. * Patient must not be on any anti-diabetes medications prior to index PDM date. * Patient must not be on chronic or acute use of steroid medications ≤90 days prior to the index PDM date. \*Allowed: Nasal, topical steroids, oral budesonide, ophthalmic * Patient must not have had an intra-articular steroid injection ≤ 7 days prior to the index PDM date. * Patient must have values available in the EMR to calculate the ENDPAC score.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Diabetes mellitus are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Baylor College of Medicine
Houston, Texas, 77030, United States
-
Kaiser Permanente Southern California, Kaiser Permanente Research
Pasadena, California, 91101, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can coconut oil and moringa rinses fight gum disease in diabetic kids?
- Eye scans as a window to the body: study probes retinal imaging across diseases
- A routine blood count may reveal how severe diabetic ketoacidosis will be
- Smart pillbox aims to keep patients on track
- Can a simple risk score keep breast cancer patients on their targeted therapy?
- Can a glucose app that predicts lows calm diabetes fears?